JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Ipamorelin represents a synthetic pentapeptide research compound extensively studied in cell-based assay formats for its selective growth hormone secretagogue receptor-1a (GHSR-1a) activity. This compound demonstrates distinct pharmacological characteristics through class A G-protein coupled receptor mechanisms, specifically engaging Gq/11 protein coupling and downstream calcium mobilization pathways. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream signaling cascade engagement in defined cell model systems under controlled laboratory conditions.
Ipamorelin exhibits selective binding affinity for the GHSR-1a receptor subtype, a class A G-protein coupled receptor expressed predominantly in pituitary somatotroph cell populations. Competitive radioligand binding assays demonstrate high selectivity coefficients when compared to related peptide hormone receptors within the secretagogue family. The compound displays nanomolar binding constants in transfected cell expression systems, with Ki values typically ranging between 0.38-1.2 nM depending on cell line characteristics and assay conditions.
Saturation binding experiments reveal single-site binding kinetics consistent with orthosteric site engagement. Association and dissociation rate constants indicate relatively rapid receptor binding kinetics, with kon values approximating 10^7 M-1s-1 and koff rates supporting receptor residence times consistent with physiological signaling requirements.
GHSR-1a activation by ipamorelin preferentially couples through Gq/11 protein subunits, initiating phospholipase C-beta activation and subsequent inositol trisphosphate (IP3) generation. Calcium mobilization assays in GHSR-1a-transfected cell lines demonstrate robust intracellular calcium release from endoplasmic reticulum stores, with EC50 values typically ranging from 0.1-0.8 nM across different experimental systems.
Secondary messenger cascades involve protein kinase C activation through diacylglycerol production, contributing to downstream phosphorylation events relevant to growth hormone synthesis and secretion machinery. Cyclic adenosine monophosphate (cAMP) measurements indicate minimal adenylyl cyclase activation, confirming primary Gq/11 coupling selectivity over Gs protein pathways.
Isolated pituitary somatotroph preparations serve as primary research models for ipamorelin pharmacological characterization. These cell systems maintain endogenous GHSR-1a expression profiles and downstream signaling architecture necessary for growth hormone synthesis and secretion processes. Calcium imaging studies in primary somatotrophs reveal concentration-dependent responses with maintained receptor sensitivity across multiple stimulation cycles.
Dispersed pituitary cell cultures enable investigation of ipamorelin effects on growth hormone mRNA expression through quantitative PCR methodologies. Time-course studies demonstrate rapid increases in growth hormone transcript levels following receptor activation, consistent with transcriptional regulation mechanisms.
HEK293 cells stably expressing human GHSR-1a provide standardized platforms for receptor pharmacology investigations. These systems enable precise control of receptor expression levels and elimination of endogenous receptor background activity. Luciferase reporter assays linked to growth hormone promoter sequences facilitate quantitative assessment of transcriptional activation following ipamorelin treatment.
CHO cell expression systems offer alternative platforms for binding affinity determinations and functional assay development. These models support high-throughput screening applications and structure-activity relationship studies when combined with ipamorelin analogue libraries.
Kinetic binding analysis reveals ipamorelin association rates consistent with diffusion-limited receptor engagement, while dissociation kinetics indicate moderate receptor residence times supporting sustained signaling activation. Temperature-dependent binding studies demonstrate thermodynamically favorable receptor interactions with negative enthalpy changes characteristic of peptide-receptor recognition events.
Competition binding experiments with endogenous ghrelin demonstrate competitive inhibition patterns, confirming orthosteric site binding mechanisms. Hill coefficients approximate unity, indicating non-cooperative binding behavior consistent with single receptor binding sites.
Phospholipase C-beta enzyme kinetics following GHSR-1a activation reveal concentration-dependent increases in activity with Michaelis-Menten parameters consistent with physiological calcium mobilization requirements. Protein kinase C activation kinetics demonstrate time-dependent increases in enzymatic activity correlating with diacylglycerol generation profiles.
Ipamorelin demonstrates selective GHSR-1a receptor pharmacology through high-affinity binding and preferential Gq/11 protein coupling mechanisms. In vitro characterization reveals robust calcium mobilization responses, transcriptional activation of growth hormone expression, and sustained receptor signaling in both primary pituitary cell models and transfected expression systems. These pharmacological properties establish ipamorelin as a valuable research tool for investigating growth hormone secretagogue receptor signaling pathways and related cellular mechanisms in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.